Category: Tengion Inc.
Tengion's clinical trial of its Neo-Urinary Conduit system will continue after 2 of the 6 enrolled patients died from causes unrelated to the trial.
Tengion (NSDQ:TNGN) plans to complete enrollment its in Neo-Urinary Conduit clinical trial following the deaths of 2 of the 6 enrolled patients after deeming the deaths unrelated to the device or surgical procedure.
Medtronic touts news study results comparing its Resolute drug-eluting stent in patients with and without diabetes; also, Tengion struggles, but may find refuge in Medtronic; Uroplasty soars on 40% boost in Q4 sales; NeuroMetrix targets investors; Allscripts shareholders launch proxy war; plus, a Funding Roundup and analysts' ups and downs.
Medtronic (NYSE:MDT) touted new study results for its Resolute drug-eluting stents, the 1st with FDA indication for treatment of patients with diabetes.
The Obama administration defends the insurance mandate portion of its health care reform law in a Supreme Court briefing.
MASSDEVICE ON CALL — In a Supreme Court briefing on Friday, the Obama administration defended its health care reform law, arguing that the Supreme Court would need to break with clear precedent in order to justify cutting down the insurance mandate.
The health care law requires most all Americans to purchase health insurance or pay a penalty, which the Justice Department defines as an unconstitutional tax. GOP lawmakers are urging the Supreme Court to strike down the entire Affordable Care Act if the individual mandate is deemed unconstitutional.
Tengion announces new CEO following the resignation of Steven Nichtberger amid a harsh third quarter.
Tengion Inc. (NSDQ:TNGN) handed veteran med-tech executive John Miclot the keys to the corner office this week, following a tough third quarter that saw the resignation of former CEO Steven Nichtberger.
Nichtberger stepped down mid-August without official explanation.
Zoll's stock jumped by nearly a quarter overnight after the release of its 2011 earnings report revealing record sales and profits for 2011; plus, Bovie Medical's Q3 profits soar despite sales slide; Cardium Therapeutics pares Q3 losses; Daxor Corp. swings to Q3 loss; Derma Sciences grows Q3 sales, losses; Edap swings to Q3 profits; Fonar Corp.'s Q1 sales, earnings rise; sales plunge as Imris swings to Q3 red; InspireMD's Q3 sales, losses increase; Oridion's Q3 sales, earnings rise; sales down as Patient Safety Technologies swings to Q3 loss; PLC Systems boosts Q3 sales, losses soar; Sanuwave cuts Q3 losses despite lower sales; and Tengion's Q3 losses mount.
Zoll reported record numbers in its top and bottom line for fiscal year 2011, sending its stock up 23 percent overnight.
Zoll shares were trading at $44.35 in the early afternoon today, up from last night's $35.98 close.
The company's 2011 sales hit a record high of $523.7 million, 18 percent higher than the $444 million posted last year.
